Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.
The partnership aims to co-develop full-stack AI infrastructure, targeting enterprise and industrial use cases in Japan and beyond.
The ISM Services PMI unexpectedly fell to the breakeven point of 50, missing market forecasts and raising new questions about US economic momentum.
Zepzelca, in combination with Roche's Tecentriq, is the first approved first-line maintenance therapy for extensive-stage small cell lung cancer.
ProSense cryoablation system gains marketing authorization as the first minimally invasive treatment for low-risk tumors in women over 70.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
GM, Ford, and Stellantis shares climb on news of potential tariff exemptions for U.S. vehicles, signaling a policy shift.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.